Trial Profile
Phase II study of avelumab in metastatic gastronetro-pancreatic GEP neuroendocrine carcinoma NEC, WHO grade 3 as second-line treatment after failing to etoposide+cisplatin: integration of genomic analysis to identify predictive molecular subtypes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Dec 2019
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 26 Dec 2019 Status changed from recruiting to completed.
- 14 Jan 2018 Status changed from not yet recruiting to recruiting.
- 12 May 2017 New trial record